He noted significant advancements in operational excellence, customer collaboration, and innovation, including the NovaSeq X transition and new partnerships. Illumina reported Q4 revenue of $1.1 ...

In addition, the new NovaSeq X 25B 100 and 200-cycle ... In November 2024, Illumina announced TruSight Oncology 500 v2 (TSO 500 v2), a new version of its flagship cancer research assay to enable ...

Q4 2024 Earnings Call Transcript February 6, 2025 Illumina, Inc. misses on earnings expectations. Reported EPS is $0.91 EPS, ...

Illumina (ILMN) announced a series of updates to its NovaSeq X Series, delivering the NovaSeq X single-flow-cell system alongside a software upgrade and new kits. The single-flow-cell NovaSeq X ...

Further innovation, like the NovaSeq, continue to push down ... issued debt ($500 million due in 2023 and $500 million due in 2031). We think Illumina should be able to handle this mild increase ...

New NovaSeq X 25B 100-cycle and 200-cycle kits enhance multiomic capabilities on NovaSeq X, and enable newly released Illumina Single-Cell Prep SAN DIEGO, Jan. 7, 2025 /PRNewswire/ -- Illumina ...

Illumina, Inc. ILMN has announced a series of updates to its NovaSeq X Series. The company’s single-flow-cell NovaSeq X Sequencing System is now available for the first time, alongside the ...

Please be advised that today's conference is being recorded. I would now like to hand the conference over to Sally Schwartz, Vice President of Investor Relations. Hello everyone and welcome to our ...

New NovaSeq X 25B 100-cycle and 200-cycle kits enhance multiomic capabilities on NovaSeq X, and enable newly released Illumina Single-Cell Prep SAN DIEGO, Jan. 7, 2025 /PRNewswire/ -- Illumina, Inc.